Lucerastat Shows Exploratory Renal Signals in Fabry Disease: Study
Canada: Lucerastat, an oral substrate reduction therapy, failed to meet its primary endpoint for neuropathic pain in adults with Fabry disease, but demonstrated encouraging biochemical effects and a possible signal…